The FDA subsequently granted approval for neoadjuvant durvalumab with platinum-containing chemotherapy followed by adjuvant durvalumab treatment in non-ALK/EGFR altered NSCLC with resectable tumors ≥ 4 cm and/or node involvement [40]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.